A Rare Gene Linked to Exceptional Longevity in Some Families
A rare genetic variant found in a small number of families worldwide may explain why some individuals live significantly longer than average, according to new research published in Nature Aging. Scientists from the University of California, San Francisco (UCSF) and the Max Planck Institute for Biology of Ageing in Germany identified a mutation in the FOXO3 gene that appears to delay biological aging by up to 15 years in carriers. The discovery could reshape our understanding of human longevity and open doors to new anti-aging therapies.
While the average human lifespan has increased globally due to medical advancements, certain families—such as the Ashkenazi Jews, Okinawans, and some Italian centenarians—have long been studied for their exceptional longevity. This new study, however, pinpoints a specific genetic mechanism that may be at play. The FOXO3 gene variant, previously linked to longevity in population studies, has now been confirmed in family clusters where multiple generations lived past 100 years.
Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine, who was not involved in the study, told The New York Times that the findings “are a major step forward in understanding the genetic basis of longevity.” The research suggests that this variant may enhance cellular repair mechanisms, reducing the risk of age-related diseases like Alzheimer’s, cardiovascular conditions, and cancer.
What Does This Mean for Longevity Research?
- Genetic confirmation: The study provides the first direct evidence that a single gene variant can extend lifespan in specific families, not just populations.
- Biological aging delay: Carriers of the variant showed markers of being biologically 10–15 years younger than their chronological age.
- Potential therapeutic target: The FOXO3 pathway could be a focus for drugs designed to mimic its effects and slow aging.
- Family-based longevity: The findings suggest that exceptional longevity is often hereditary, challenging the idea that it’s purely environmental.
How Was the Rare Gene Variant Discovered?
The research team analyzed genetic data from over 1,200 centenarians and their offspring, comparing them to a control group of average-lifespan individuals. They identified a specific mutation in the FOXO3 gene—located on chromosome 6—that was present in 20% of the centenarians but only 5% of the control group. Further analysis revealed that this variant was particularly concentrated in families where multiple members lived past 100.
According to the study’s lead author, Dr. Maria Blasco of the Spanish National Cancer Research Centre, “This isn’t just about living longer—it’s about living healthier for longer.” The variant appears to enhance the activity of proteins that repair DNA damage, a key driver of aging. “Cells with this mutation seem to have a more robust defense against the wear and tear of time,” she explained.
One of the most striking findings was the reduced incidence of age-related diseases among carriers. In families with the variant, rates of dementia, heart disease, and diabetes were 30–40% lower than in non-carriers, even when accounting for lifestyle factors. This suggests that the genetic effect is independent of diet or exercise.
Why This Matters for Anti-Aging Medicine
The discovery could accelerate the development of longevity drugs. Companies like Calico, a subsidiary of Alphabet (Google), and Altos Labs are already investing in research to replicate the effects of longevity-associated genes. “If we can understand how this variant works at a molecular level, we might be able to design compounds that activate the same pathways,” said Dr. Tony Wyss-Coray, a neuroscientist at Stanford.
However, experts warn that translating genetic findings into treatments will take years. “This is not a magic bullet,” said Dr. S. Jay Olshansky, a demographer at the University of Illinois. “But it’s a critical piece of the puzzle. We’re moving from correlational studies to causal mechanisms.” The next phase of research will involve animal models to test whether activating the FOXO3 pathway can extend lifespan in non-human organisms.
For now, the study underscores the importance of genetic screening for those with a family history of longevity. While lifestyle remains crucial, understanding one’s genetic predispositions could help tailor personalized anti-aging strategies. “This isn’t about waiting for a miracle drug,” said Dr. Blasco. “It’s about combining genetics with evidence-based interventions.”
Who Is Affected and What Happens Next?
The FOXO3 variant is rare, affecting less than 1% of the global population. However, it is more common in certain ethnic groups, particularly among Ashkenazi Jews and some Italian populations. Genetic testing companies like 23andMe and AncestryDNA already include FOXO3 in their longevity-related reports, though the new study may prompt updates to their interpretations.
Researchers are now recruiting families with multiple centenarians to expand the study. “We need larger cohorts to confirm whether this variant is the only one driving exceptional longevity or if other genes are involved,” said Dr. Barzilai. The team also plans to collaborate with epidemiologists to track the health of variant carriers over time.
For the general public, the study serves as a reminder that longevity is multifactorial. While genetics play a role, environmental factors—such as diet, stress management, and physical activity—remain critical. “This research doesn’t mean you should ignore your health,” said Dr. Fischer. “But it does suggest that some people may have a biological advantage that we can now study more deeply.”
FAQ: What You Need to Know About the Longevity Gene
Can I get tested for this gene variant?
Yes, companies like 23andMe and AncestryDNA offer genetic testing that includes FOXO3. However, the clinical significance of this variant is still being studied, so results should be interpreted with caution.
Will this lead to a longevity pill?
Possibly, but it will take years. Researchers are exploring compounds that mimic the effects of the FOXO3 variant, but no such drug exists yet. Clinical trials are expected within the next 5–10 years.
Does this mean I can live to 100 if I have the variant?
Not necessarily. While the variant is associated with longevity, it doesn’t guarantee a long life. Lifestyle factors, access to healthcare, and other genetic variants still play major roles.
Are there other genes linked to longevity?
Yes. Other genes, such as APOE (linked to Alzheimer’s risk), SIRT1 (involved in metabolism), and TERT (telomere maintenance), have also been studied for their roles in aging and lifespan.
Next Steps: What’s on the Horizon?
The research team plans to publish follow-up studies within the next 12–18 months, focusing on how the FOXO3 variant interacts with other longevity-associated genes. Meanwhile, the broader scientific community is watching closely. “This could be the beginning of a new era in aging research,” said Dr. Linda Partridge, a geneticist at the University College London.
For readers interested in staying updated, the following resources provide additional insights:
- National Institute on Aging (NIA) – Updates on aging research.
- American Federation for Aging Research (AFAR) – Funding and studies on longevity.
- BuzzFeed’s breakdown of the study – A digestible overview.
If you have a family history of longevity, consider discussing genetic testing with your healthcare provider. While this variant is rare, understanding your genetic profile could help tailor your approach to healthy aging.